Fujitsu Launches New Version of Microinjection Tech; Claims 2X Efficiency in Transfecting Problem Cells | GenomeWeb

Fujitsu's Biosciences Group this week launched a new version of its automated microinjection technology that will allow users to transfect adherent cells without having to first trypsinize them to release them from their growth surface.

The new platform, which Fujitsu says nearly doubles the transformation efficiency in difficult-to-transfect cell types, could allow Fujitsu to better compete with vendors such as Cellectricon and Cyntellect that have already developed alternative high-throughput transfection methods for such cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.